FATE Insider Trading
FATE THERAPEUTICS INC | Biological Products, (No Diagnostic Substances)
Comprehensive Trading Performance Summary
The investment history of corporate insiders at FATE THERAPEUTICS INC provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Biological Products, (No Diagnostic Substances) sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2022-06-06 23:45 | 2022-06-03 | HERSHBERG ROBERT | Director | SELL | $22.75 | 672 | $15,288 | 2,009 | -25.1% |
| 2022-06-06 23:49 | 2022-06-03 | MENDLEIN JOHN | Director | SELL | $22.79 | 1,364 | $31,086 | 158,091 | -0.9% |
| 2022-06-02 23:04 | 2022-06-01 | TAHL CINDY | Officer - General Counsel and Secretary | OPT+S | $22.96 | 25,000 | $574,000 | 189,151 | 0.0% |
| 2022-04-25 23:11 | 2022-04-21 | Wolchko J Scott | Director, Officer - President and CEO | OPT+S | $34.89 | 40,000 | $1,395,792 | 431,546 | 0.0% |
| 2022-04-21 23:04 | 2022-04-19 | Chu Yu-Waye | Officer - Chief Medical Officer | SELL | $35.37 | 4,062 | $143,673 | 151,033 | -2.6% |
| 2022-04-05 00:01 | 2022-04-01 | TAHL CINDY | Officer - General Counsel and Secretary | OPT+S | $38.85 | 25,000 | $971,250 | 189,151 | 0.0% |
| 2022-03-15 23:27 | 2022-03-14 | Valamehr Bahram | Officer - Chief R&D Officer | OPT+S | $31.07 | 25,000 | $776,733 | 179,834 | 0.0% |
| 2022-03-12 00:58 | 2022-03-10 | MENDLEIN JOHN | Director | OPT+S | $35.02 | 31,562 | $1,105,200 | 159,455 | 0.0% |
| 2022-01-25 00:36 | 2022-01-20 | Wolchko J Scott | Director, Officer - President and CEO | OPT+S | $39.66 | 40,000 | $1,586,500 | 431,546 | 0.0% |
| 2022-01-14 00:09 | 2022-01-11 | Wolchko J Scott | Director, Officer - President and CEO | SELL | $48.68 | 14,566 | $709,026 | 431,546 | -3.3% |
| 2022-01-14 00:08 | 2022-01-11 | TAHL CINDY | Officer - General Counsel and Secretary | SELL | $48.53 | 5,419 | $262,974 | 155,849 | -3.4% |
| 2022-01-14 00:07 | 2022-01-11 | Valamehr Bahram | Officer - Chief R&D Officer | SELL | $48.50 | 4,570 | $221,655 | 146,532 | -3.0% |
| 2022-01-14 00:06 | 2022-01-11 | Dulac Edward J III | Officer - Chief Financial Officer | SELL | $48.45 | 1,770 | $85,757 | 108,634 | -1.6% |
| 2022-01-14 00:05 | 2022-01-11 | Chu Yu-Waye | Officer - Senior VP Clinical Development | SELL | $48.51 | 3,965 | $192,341 | 121,793 | -3.2% |
| 2022-01-13 00:07 | 2022-01-10 | Wolchko J Scott | Director, Officer - President and CEO | SELL | $46.86 | 34,156 | $1,600,533 | 446,112 | -7.1% |
| 2022-01-13 00:06 | 2022-01-10 | TAHL CINDY | Officer - General Counsel and Secretary | SELL | $46.43 | 7,738 | $359,312 | 161,268 | -4.6% |
| 2022-01-13 00:05 | 2022-01-10 | Valamehr Bahram | Officer - Chief R&D Officer | SELL | $46.38 | 5,596 | $259,558 | 151,102 | -3.6% |
| 2022-01-05 00:03 | 2022-01-03 | TAHL CINDY | Officer - General Counsel and Secretary | OPT+S | $59.34 | 50,000 | $2,966,855 | 169,006 | 0.0% |
| 2021-12-22 00:08 | 2021-12-20 | Dulac Edward J III | Officer - Chief Financial Officer | OPT+S | $60.00 | 15,977 | $958,620 | 110,404 | 0.0% |
| 2021-12-15 00:18 | 2021-12-13 | Valamehr Bahram | Officer - Chief R&D Officer | OPT+S | $47.66 | 25,000 | $1,191,405 | 156,698 | 0.0% |
| 2021-12-14 01:53 | 2021-12-10 | Chu Yu-Waye | Officer - Senior VP Clinical Development | OPT+S | $51.46 | 7,500 | $385,948 | 125,758 | 0.0% |
| 2021-11-23 01:45 | 2021-11-18 | Wolchko J Scott | Director, Officer - President and CEO | OPT+S | $54.27 | 20,000 | $1,085,400 | 393,793 | 0.0% |
| 2021-10-25 23:04 | 2021-10-21 | Wolchko J Scott | Director, Officer - President and CEO | OPT+S | $59.55 | 60,000 | $3,572,958 | 393,793 | 0.0% |
| 2021-10-04 23:12 | 2021-10-01 | TAHL CINDY | Officer - General Counsel and Secretary | OPT+S | $58.83 | 50,000 | $2,941,460 | 108,048 | 0.0% |
| 2021-09-30 23:14 | 2021-09-28 | Dulac Edward J III | Officer - Chief Financial Officer | OPT+S | $62.53 | 19,460 | $1,216,834 | 52,404 | 0.0% |
| 2021-09-14 23:01 | 2021-09-13 | Valamehr Bahram | Officer - Chief Development Officer | OPT+S | $66.29 | 25,000 | $1,657,258 | 95,740 | 0.0% |
| 2021-08-20 23:02 | 2021-08-19 | Wolchko J Scott | Director, Officer - President and CEO | OPT+S | $88.01 | 20,000 | $1,760,204 | 393,793 | 0.0% |
| 2021-08-20 23:01 | 2021-08-19 | Dulac Edward J III | Officer - Chief Financial Officer | SELL | $88.26 | 3,474 | $306,602 | 54,539 | -6.0% |
| 2021-07-26 23:05 | 2021-07-22 | Wolchko J Scott | Director, Officer - President and CEO | OPT+S | $85.67 | 60,000 | $5,140,116 | 393,793 | 0.0% |
| 2021-07-03 02:08 | 2021-07-01 | TAHL CINDY | Officer - General Counsel and Secretary | OPT+S | $85.24 | 55,534 | $4,733,746 | 108,048 | 0.0% |
| 2021-06-16 23:26 | 2021-06-14 | Valamehr Bahram | Officer - Chief Development Officer | OPT+S | $89.32 | 25,000 | $2,233,045 | 95,740 | 0.0% |
| 2021-05-24 23:01 | 2021-05-20 | Wolchko J Scott | Director, Officer - President and CEO | OPT+S | $77.16 | 20,000 | $1,543,292 | 393,793 | 0.0% |
| 2021-04-26 23:03 | 2021-04-22 | Wolchko J Scott | Director, Officer - President and CEO | OPT+S | $85.39 | 60,000 | $5,123,496 | 393,793 | 0.0% |
| 2021-04-20 23:00 | 2021-04-16 | Chu Yu-Waye | Officer - Senior VP Clinical Development | SELL | $83.30 | 3,275 | $272,809 | 64,800 | -4.8% |
| 2021-04-03 01:03 | 2021-04-01 | TAHL CINDY | Officer - See Remarks | OPT+S | $83.81 | 30,000 | $2,514,330 | 108,048 | 0.0% |
| 2021-03-16 23:05 | 2021-03-15 | Valamehr Bahram | Officer - Chief Development Officer | OPT+S | $92.35 | 25,000 | $2,308,773 | 95,740 | 0.0% |
| 2021-03-10 00:02 | 2021-03-08 | Shoemaker Daniel D | Officer - Chief Scientific Officer | SELL | $81.74 | 25,000 | $2,043,428 | 73,020 | -25.5% |
| 2021-02-20 00:07 | 2021-02-18 | Wolchko J Scott | Director, Officer - President and CEO | OPT+S | $102.01 | 20,000 | $2,040,258 | 393,793 | 0.0% |
| 2021-01-23 02:23 | 2021-01-21 | Wolchko J Scott | Director, Officer - President and CEO | OPT+S | $100.67 | 60,000 | $6,039,966 | 393,793 | 0.0% |
| 2021-01-22 03:08 | 2021-01-19 | TAHL CINDY | Officer - General Counsel and Secretary | OPT+S | $114.76 | 35,000 | $4,016,639 | 90,035 | 0.0% |
| 2021-01-13 04:41 | 2021-01-08 | Wolchko J Scott | Director, Officer - President and CEO | SELL | $116.33 | 69,407 | $8,073,769 | 350,562 | -16.5% |
| 2021-01-13 04:40 | 2021-01-08 | Valamehr Bahram | Officer - Chief Development Officer | SELL | $114.95 | 9,484 | $1,090,140 | 77,727 | -10.9% |
| 2021-01-13 04:39 | 2021-01-08 | TAHL CINDY | Officer - General Counsel and Secretary | SELL | $114.94 | 9,483 | $1,090,022 | 90,035 | -9.5% |
| 2021-01-13 04:38 | 2021-01-08 | Shoemaker Daniel D | Officer - Chief Scientific Officer | SELL | $114.95 | 9,482 | $1,089,911 | 83,609 | -10.2% |
| 2021-01-13 00:16 | 2021-01-08 | Redmile Group, LLC | Director, 10% owner | BUY | $85.50 | 327,485 | $27,999,968 | 12,957,222 | +2.6% |
| 2020-12-19 00:01 | 2020-12-17 | Wolchko J Scott | Director, Officer - President and CEO | OPT+S | $91.82 | 20,000 | $1,836,352 | 419,969 | 0.0% |
| 2020-12-16 00:01 | 2020-12-14 | Valamehr Bahram | Officer - Chief Development Officer | OPT+S | $97.78 | 25,000 | $2,444,478 | 87,211 | 0.0% |
| 2020-11-17 01:12 | 2020-11-16 | Shoemaker Daniel D | Officer - Chief Scientific Officer | SELL | $51.83 | 25,000 | $1,295,745 | 93,091 | -21.2% |
| 2020-11-17 00:02 | 2020-11-12 | Wolchko J Scott | Director, Officer - President and CEO | OPT+S | $51.87 | 60,000 | $3,112,422 | 419,969 | 0.0% |
| 2020-11-07 00:02 | 2020-11-04 | TAHL CINDY | Officer - General Counsel and Secretary | OPT+S | $50.47 | 70,801 | $3,573,390 | 99,518 | 0.0% |
How to Interpret $FATE Trades
Not every insider transaction in FATE THERAPEUTICS INC is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $FATE shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for FATE
Insider activity data for FATE THERAPEUTICS INC is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $FATE, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.